OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S
Advertisement
OctoPlus N.V. announced that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
OSI Pharmaceuticals, Inc. - Melville, USA
Paloma Pharmaceuticals, Inc. - Jamaica Plain, USA
Neurotech Pharmaceuticals, Inc. - Lincoln, RI, USA
ZERMEC Pharma AG - Laufenburg, Switzerland
Neuenhauser Automation GmbH - Naila, Germany
Oncos Therapeutics Ltd. - Helsinki, Finland
Oncotec Pharma Produktion GmbH - Roßlau, Germany
FRÜH VERPACKUNGSTECHNIK AG - Fehraltorf, Switzerland